COVID-19 vaccine, which should help determine the vaccine's efficacy.Moderna said the information is being prepared for submission to the trial's independent data safety monitoring board, which will look at the results and make a recommendation.
It did not say when it plans to release the efficacy data.The company said in a news release that it has seen a significant increase in the number of COVID-19 cases among trial participants as infection rates have surged around the United States.Due to the spike in cases, the analysis will cover substantially more than 53 infections, which had been the targeted trigger point for the first analysis.The company said the trial remains blinded, so neither it nor study investigators know which.